Premium
Hyperleukocytosis from arsenic trioxide
Author(s) -
Levy Michael,
Wofford Marcia M.,
Powell Bayard L.,
McLean Thomas W.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21532
Subject(s) - arsenic trioxide , medicine , acute promyelocytic leukemia , blood cancer , arsenic , gastroenterology , cancer , retinoic acid , biochemistry , materials science , chemistry , metallurgy , gene
We report the case of a 14‐year‐old male treated with arsenic trioxide for recurrent acute promyelocytic leukemia. He developed hyperleukocytosis (WBC 111.6 × 10 9 /L) which then resolved while continuing daily arsenic. Hyperleukocytosis without other complications may not be an indication for adding cytotoxic therapy or steroids, nor for discontinuing arsenic trioxide therapy in children. Pediatr Blood Cancer 2008;50:1265–1267. © 2008 Wiley‐Liss, Inc.